The FOURIER study and ODYSSEY study have also established the PCSK9 antibody’s position in the therapy of hypercholesterolemia and prevention of atherosclerotic coronary artery disease (ASCVD) and stroke [48–50]. Here, PCSK9 is linked to familial hypercholesterolemia.